SOUTH SAN FRANCISCO, Calif., Feb. 21 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. , today announced that Stephen A. Sherwin, M.D., chairman and chief executive officer, and Sharon E. Tetlow, senior vice president and chief financial officer of Cell Genesys, will host a conference call relating to the company’s fourth quarter and year-end financial results that will be broadcast live over the internet on Thursday, February 28, 2008, at 2:00 p.m. PT/ 5:00 p.m. ET.
The webcast will be available on the investor relations section of the company’s website, http://www.cellgenesys.com. If you are unable to listen to the live webcast, the call will be archived on the website for at least 72 hours following the call. To access the replay, go to the Investor Relations section of the website.
Cell Genesys is focused on the development and commercialization of novel biological therapies for patients with cancer. The company is currently pursuing two clinical stage product platforms -- GVAX(TM) cancer immunotherapies and oncolytic virus therapies. Ongoing clinical trials include Phase 3 trials of GVAX immunotherapy for prostate cancer, Phase 2 trials of GVAX immunotherapies for pancreatic cancer and for leukemia, and a Phase 1 trial of CG0070 oncolytic virus therapy for bladder cancer. Cell Genesys continues to hold an equity interest in its former subsidiary, Ceregene, Inc., which is developing gene therapies for neurodegenerative disorders. Cell Genesys is headquartered in South San Francisco, CA and has its principal manufacturing operation in Hayward, CA. For additional information, please visit the company’s website at http://www.cellgenesys.com.
CONTACT: Susan Ferris, Investor Relations of Cell Genesys, Inc.,
+1-650-266-3200
Web site: http://www.cellgenesys.com/
